Cadila's U.S. facility in St. Louis cited by FDA for 11 observations: report

chickenpox vaccine
Cadila's U.S. manufacturing facility was cited by the FDA for 11 observations on the heels of 14 citations last month for one of its India plants. (Cadila)

Cadila Healthcare’s U.S. drug manufacturing facility in St. Louis was cited by the FDA for observations in the wake of the company’s Moraiya, India, plant getting tagged by the regulatory agency for a dozen observations last month.

In a Bombay Stock Exchange filing cited by the Business Standard, the company said the inspection of its Nesher Pharmaceuticals sites by the FDA between May 13 and May 31 resulted in a total of 11 observations.

Nesher is a wholly owned subsidiary of Cadila.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“The inspection concluded with 3 observations at one (Nesher) facility and 8 observations at the other” the company said in the filing. The agency issued the observations with a recommendation for Voluntary Action Indicated, the company said.

Cadila said the inspections were product-specific and pre-approval with general current good manufacturing practice, and there were no observations related to data integrity, the Standard reported.

RELATED: Cadila Moraiya plant hit with 14 observations, but no repeats, it says

In early May, Cadila reported a two-week FDA inspection of its Moraiya formulation facility received 14 observations but that it was “confident” it would be able to fix them.

The largest facility in India that makes drugs for the U.S. market, the Moraiya plant was one of two that were hit with a warning letter in late 2015 for a number of issues. Problems have also been found at other Cadila manufacturing sites, including a sterile injectables plant in Vadodara, India.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.